Drugs / LB4330
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05707676 | Nov 2022 → Dec 2024 | cancer | L & L Bio Co., Ltd., Ningbo, China | Terminated | No outcome recorded Stop: Business |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06468358 | Jun 2024 → Dec 2026 expected | cancer | L & L Bio Co., Ltd., Ningbo, China | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07177716 | Oct 2025 → Dec 2028 expected | cervical cancer | L & L Bio Co., Ltd., Ningbo, China | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LB4330 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05707676 ↗ |
| Action | Activate | “CD8 T cell activator” NCT05707676 ↗ |
| Modality | Protein / enzyme biologic | “anti-Claudin 18.2 and CD8 T cell activator fusion protein” NCT05707676 ↗ |
| Route | Intravenous | “LB4330 administered intravenously (IV)” NCT05707676 ↗ |
| Target | CLDN18 | “anti-claudin18.2/IL-10 fusion protein” NCT06468358 ↗ |